Inhibition of in vivo tumor growth by a monoclonal IgM antibody recognizing tumor cell surface carbohydrates
- PMID: 2224860
Inhibition of in vivo tumor growth by a monoclonal IgM antibody recognizing tumor cell surface carbohydrates
Abstract
We have shown previously that IgM from Ehrlich tumor (ET)-immunized mice, recognizing ET cell surface carbohydrates, protects control mice to a subsequent tumor challenge. The factors involved in such IgM-mediated protection were unknown, since it was independent of complement activation. Here, we have extended these in vivo studies by means of monoclonal IgM antibodies. Two of them (A10 and E1), strongly recognizing ET cells and with specificity to ET cell surface carbohydrates, were selected. The results show that A10 (but not E1 or unrelated IgM antibodies) is able to protect nonimmunized mice against ET growth. Protection by A10 was also seen by reducing 800-fold the initial dose; however, E1 was unsuccessful whatever the dose used. A10-mediated protection was observed in C3-defective mice (cobra venom factor treated) or in C5-deficient DBA/2, but not in silica-treated animals. Endotoxin removal did not affect the protection afforded by A10 while specific IgM depletion prevented any protective effect. In addition, the relationship between natural antibodies of IgM isotype recognizing ET cell surface carbohydrates and mouse strain resistance to this tumor is established. Similarly, this natural resistance seems to be complement independent but macrophage mediated. Therefore, these results indicate that some IgM molecules recognizing cell surface carbohydrates may participate in in vivo tumor suppression by a macrophage-dependent mechanism.
Similar articles
-
Tumor cytostasis mediated by a monoclonal IgM antibody promoting adhesion between macrophages and tumor cells. Evidence for a lectin-like behavior.J Immunol. 1992 Apr 15;148(8):2636-42. J Immunol. 1992. PMID: 1560214
-
Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.Oncogene. 1988 Apr;2(4):387-94. Oncogene. 1988. PMID: 2896329
-
Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.Cancer Res. 1985 Apr;45(4):1663-8. Cancer Res. 1985. PMID: 3978634
-
Natural human immunoglobulins in cancer immunotherapy.Immunotherapy. 2009 Mar;1(2):241-8. doi: 10.2217/1750743X.1.2.241. Immunotherapy. 2009. PMID: 20635944 Review.
-
Mechanisms of tumor immunity: the role of antibody and nonimmune effectors.Prog Allergy. 1978;25:163-210. Prog Allergy. 1978. PMID: 362428 Review. No abstract available.
Cited by
-
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.Neoplasia. 2006 Jan;8(1):69-78. doi: 10.1593/neo.05679. Neoplasia. 2006. PMID: 16533428 Free PMC article.
-
Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis.J Cell Biol. 1993 Sep;122(6):1351-9. doi: 10.1083/jcb.122.6.1351. J Cell Biol. 1993. PMID: 8376467 Free PMC article.
-
Bridging innate and adaptive antitumor immunity targeting glycans.J Biomed Biotechnol. 2010;2010:354068. doi: 10.1155/2010/354068. Epub 2010 Jun 15. J Biomed Biotechnol. 2010. PMID: 20617150 Free PMC article. Review.
-
Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.Transl Oncol. 2010 Aug 1;3(4):204-17. doi: 10.1593/tlo.09316. Transl Oncol. 2010. PMID: 20689762 Free PMC article.
-
Monoclonal antibodies that recognize the trisaccharide epitope Gal alpha 1-3Gal beta 1-4GlcNAc present on Ehrlich tumor cell membrane glycoproteins.Histochemistry. 1993 Aug;100(2):139-47. doi: 10.1007/BF00572900. Histochemistry. 1993. PMID: 7503969
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous